/PRNewswire/ – The board of directors of Eli Lilly and Company has elected Juan R. Luciano as a new member, effective February 1, 2016.
Luciano is chief executive officer and president of Archer Daniels Midland Company (ADM), and a member of the ADM board of directors.
“I am pleased to welcome Juan to the Lilly board,” said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. “Juan brings to the Lilly board a global perspective and a proven track record of leading high-performance, results-focused organizations. We will benefit from Juan’s broad business experience, including his knowledge of the food and agriculture sectors.”
Luciano joined ADM in 2011 as executive vice president and chief operating officer. He was named president in February 2014, and in January 2015 became the ninth chief executive in ADM’s 112-year history.
Since joining ADM, Luciano has overseen the commercial and production activities of ADM’s Corn, Oilseeds and Agricultural Services businesses, as well as its research, project management, procurement and risk management functions. He led the company’s operational excellence initiatives, which seek to improve productivity and efficiency companywide, as well as the company’s efforts to improve its capital, cost and cash positions. Luciano also led the company’s move into ingredients.
Before joining ADM, Luciano had a successful 25-year tenure at The Dow Chemical Company, where he last served as executive vice president and president of the performance division.
Luciano is a governor of the Boys and Girls Clubs of America, and Midwest chair of the organization’s National Trustees Board. He holds an industrial engineering degree from the Buenos Aires Institute of Technology.
Source: Eli Lilly and Company
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.
